Abstract: A method for ascertaining an emotional goal includes receiving, via an emotionally responsive computerized system having a user interface communicatively coupled to a networked user device including a processor device, user-input concerning a purpose of a user's interaction with a software interface. It can include registering input indicating a target person to whom the purpose of the user's interaction pertains and prompting the user to provide a root motivator comprising a root emotion or a root reason for the interaction. Some variations include generating a user-perceptible output and a set of user interface elements dependent on the root motivator along with obtaining the user's specific emotional goal with respect to the target person on the basis of user-inputs in response to a presentation of a sequence of user interface elements, to provide the user, via the software interface, a recommendation regarding a fulfillment of the specific emotional goal.

Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

Abstract: The present disclosure relates to the field of hematopoietic stem or progenitor cell transplantation. More specifically, methods, compositions and kits for improving expansion and engraftment of hematopoietic stem or progenitor cells by co-culturing and co-administering with endothelial cells are provided. The methods, compositions and kits are useful for treating various disorders relating to deficiencies in hematopoiesis caused by disease or myeloablative treatments.

Abstract: The present invention relates, in part, to blood-brain barrier-like tissues that comprise engineered E40RF1+ endothelial cells, and to various compositions and methods useful for making and using such blood-brain barrier-like tissues—both in vitro and in vivo.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: A multi-stage computing framework may allow development, in an unrestricted computing region, of one or more computing resources that are transferred to, and deployed in, a restricted computing region. The computing framework may include a development module and a transfer module. The development module may allow development of the computing resources in the unrestricted computing region, for example including stages such as a resource creation, linting, scanning, validation, packaging and requesting of the transfer. The transfer module may allow management of the transfer of the computing resources from the unrestricted computing region to the restricted computing region, for example including stages such as control, transfer request queueing, performance of the transfer, transfer notification and transfer visualization.

Abstract: The present invention provides non-thymic endothelial cells (ntECs) engineered to express adenovirus E4ORF1 and/or BMP4, and compositions comprising such engineered ntECs. The present invention also provides methods of using such ntECs in therapy, for example to enhance thymic regeneration (including T cell reconstitution) in subjects in need thereof. Such subjects include those that have a damaged thymus, defective thymic function, insufficient T-cell output, and/or that are immunocompromised—for example as a result of ageing, infection (e.g. with HIV), treatment with radiation therapy, treatment with chemotherapy, or myeloablative conditioning in preparation for an organ/tissue transplant.

Abstract: In some aspects the present invention relates to engineered endothelial cells, such as E4ORF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: The present invention relates, in part, to blood-brain barrier-like tissues that comprise engineered E40RF1+ endothelial cells, and to various compositions and methods useful for making and using such blood-brain barrier-like tissues—both in vitro and in vivo.

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: In some aspects the present invention relates to engineered endothelial cells, such as E40RF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.

Abstract: In certain aspects the present invention provides engineered neural cells, neural stem cells, or neural progenitor cells that contain a nucleotide sequence that encodes an adenovirus E40RF1 polypeptide and/or that contain an adenovirus E40RF1 polypeptide. The present invention also provides methods of making and using such engineered cells and compositions comprising such engineered cells.

Abstract: The present invention provides methods for treating spinal cord injury (SCI). Such methods involve administering E40RF1+ endothelial cells and neural cells (such as neural progenitor cells (NPCs), glial progenitor cells, or glial cells) to subjects having a SCI. The present invention also provides compositions useful in such methods, such as compositions comprising E40RF1+ endothelial cells and/or neural cells (such as NPCs, glial progenitor cells, or glial cells).

Abstract: A laser weapon system is described. Particularly, embodiments describe subsystems of a laser weapon system including those necessary for laser generation, operational control, optical emission, and heat dissipation configured to provide a lightweight unit of reduced dimensions.

Abstract: The present invention provides improved methods for gene delivery to, or genetic modification of target cells, wherein the gene delivery or other genetic modification of the target cells is performed in the presence of endothelial cells, or after co-culture of the target cells with endothelial cells, or wherein co-culture of the target cells with endothelial cells is employed immediately alter gene delivery in order to “rescue” cells that may have been damaged during the gene delivery process. In some embodiments gene delivery is performed by transfection. In some embodiments gene delivery is performed by transduction, in some embodiments the endothelial cells are organ-specific endothelial cells. In some embodiments the endothelial cells are E40RF1-expressing endothelial cells (E40RF1+ ECs). In some embodiments the target cells are stem cells, such as hematopoietic stem cells.

Abstract: A system including one or more rubber bodies with respective rubber portions. The rubber body is positionable on a preselected portion of a surface of an object. An inner side of the rubber body is engageable with the preselected portion, and an outer side thereof is opposed to the inner side. The system includes a release film positionable on the rubber body, a heating blanket positionable on the release film, and a breather fabric. The system also includes a vacuum cover engageable with the breather fabric, which is sealed along a perimeter surrounding the preselected portion of the surface. A vacuum pump is in fluid communication with an interior space partially defined by the vacuum cover, for subjecting the rubber body to a predetermined pressure. The rubber portion is vulcanizable when subjected to heat generated by the heating blanket and to the predetermined pressure.

Abstract: The present disclosure relates to the field of hematopoietic stem or progenitor cell transplantation. More specifically, methods, compositions and kits for improving expansion and engraftment of hematopoietic stem or progenitor cells by co-culturing and co-administering with endothelial cells are provided. The methods, compositions and kits are useful for treating various disorders relating to deficiencies in hematopoiesis caused by disease or myeloablative treatments.